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Abstract
Background: The current approach to screen for drug-like molecules is to sieve for molecules
with biochemical properties suitable for desirable pharmacokinetics and reduced toxicity, using
predominantly biophysical properties of chemical compounds, based on empirical rules such as
Lipinski’s “rule of five” (Ro5). For over a decade, Ro5 has been applied to combinatorial
compounds, drugs and ligands, in the search for suitable lead compounds. Unfortunately, till date, a
clear distinction between drugs and non-drugs has not been achieved. The current trend is to seek
out drugs which show metabolite-likeness. In identifying similar physicochemical characteristics,
compounds have usually been clustered based on some characteristic, to reduce the search space
presented by large molecular datasets. This paper examines the similarity of current drug
molecules with human metabolites and toxins, using a range of computed molecular descriptors as
well as the effect of comparison to clustered data compared to searches against complete datasets.
Results: We have carried out statistical and substructure functional group analyses of three
datasets, namely human metabolites, drugs and toxin molecules. The distributions of various
molecular descriptors were investigated. Our analyses show that, although the three groups are
distinct, present-day drugs are closer to toxin molecules than to metabolites. Furthermore, these
distributions are quite similar for both clustered data as well as complete or unclustered datasets.
Conclusion: The property space occupied by metabolites is dissimilar to that of drugs or toxin
molecules, with current drugs showing greater similarity to toxins than to metabolites.
Additionally, empirical rules like Ro5 can be refined to identify drugs or drug-like molecules that
are clearly distinct from toxic compounds and more metabolite-like. The inclusion of human
metabolites in this study provides a deeper insight into metabolite/drug/toxin-like properties and
w i l la l s op r o v et ob ev a l u a b l ei nt h ep r e d i c t i o no roptimization of small molecules as ligands for
therapeutic applications.
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To search for biologically active compounds, with
favorable ADMET [1] (Absorption, Distribution, Meta-
bolism, Excretion, and Toxicity) properties from the
immense “chemical space” is a non-trivial task [2]. Drug-
likeness has been dominated, in the past decade, by
Lipinski’s “Rule of Five” (Ro5) [3], which states that a
compound is likely to be “non-drug-like” if it has more
than five hydrogen bond donors, more than 10 hydro-
gen bond acceptors, molecular mass is greater than 500
and lipophilicity is above 5. The analysis carried out by
Leeson and Davis [4] of the approved drugs released
before 1983 (i.e. pre-Ro5 era) and the drugs released in
between 1983 and 2002 clearly indicates the impact of
Ro5 on drug discovery projects.
However, Lipinski’s rule has many exceptions and in one
of the studies [5] it was shown that using the above
criteria, only 66% of approved drugs in the MDL Drug
Data Report (MDDR) database, were classified as drug-
like; whereas 75% of the theoretically non-drug-like
compounds from the Available Chemical Directory
(ACD) were in fact regarded as drug-like by Ro5.
Moreover, Ro5 does not select metabolites because
metabolite-likeness is a recent measure, since Ro5 was
formulated a decade ago, with little knowledge on
metabolites and pathways. Similar studies have spurred
the quest for new approaches to classify drugs from non-
drug molecules [6,7], and to characterize the properties
of drug-like or lead-like compounds [8,9]. Subsequently,
the “rule-of-three” (Ro3) [10] was proposed for frag-
ment-based lead discovery. Ro3 states that successful hits
possess an average Molecular weight <= 300, the number
of hydrogen bond donors <= 3, the number of hydrogen
bond acceptors <= 3 and Clog P <= 3. In addition, the
number of rotatable bonds <= 3 and the polar surface
area <= 60 are also useful in characterizing drug-like and
non-drug-like molecules. In past few years, researchers
have developed a range of indices, such as the natural
product index [11], the metabolite index [12], peptide-
likeness [13], lead-likeness [14-16], and drug-likeness
[3], in an attempt to achieve a better classification
between drugs and non-drugs. In conjunction with
machine learning techniques, like Artificial Neural Net-
works (ANN) [6,7], Support Vector Machine (SVM) [17]
and Hidden Markov Models (HMM), statistical [18] and
substructure analyses have become widely accepted to
characterize the properties of drug-like datasets and
reduce the attrition rates in drug development.
Drug-likeness in natural products and synthetic
compounds
In this section, we present a summary of analysis reports
primarily focused on identifying drug-likeness in natural
products and synthetic organic compounds, derived
from combinatorial functional group replacement.
Henkeletal.[18]carriedoutstatisticalanalysistodetermine
the properties and structural differences between natural
products (NPs) and combinatorial molecules. In their
analysis, NPs were derived from Chapman and Hall
Dictionary of Natural products and the bioactive natural
product database (BNPD) obtained from Szenzor
Management Consulting Company. These were com-
pared with synthetic compounds from the Available
Chemical Directory (ACD) and Bayers database and
representative bioactive molecules from drug databases.
Stahura et al. [19] used Shannon entropy to analyze the
differences between NPs obtained from the Dictionary of
Natural Products and synthetic molecules obtained from
ACD database. Feher and Schmidt [20] examined
representative set of molecules from NPs obtained
from four databases namely BioSPECS natural product
database, ChemDiv natural product database, Interbio-
screeen IBS2001N and HTS-NC database, drugs obtained
from (Chapman and Hall Dictionary of Drugs) and
combinatorial molecules obtained from (MayBridge HTS
database, ChemBridge EXPRESS-Pick database Com-
Genex Collection, ChemDiv Collection and SPECS
screening compound database). The authors concluded
that the number of chiral centers, the number of
rotatable bonds and the ratio of aromatic atoms to
ring atoms are the most distinguishing features among
the three classes of compounds. In their study, drugs
occupied the property space between NPs and combi-
natorial compounds, consistent with drugs being
obtained from NPs as well as combinatorial libraries.
The first three principal components accounted for about
66% of the variance. Feher and Schmidt were thus the
first to introduce the idea of NP-like filters. Lee and
Schneider [21] utilized Self Organizing Maps (SOM) for
the classification of drugs, non-drugs and NPs. Their
study revealed several pharmacophoric patterns in
common between NPs and drugs, suggesting the use of
such patterns for exploring drug relevant pharmaco-
phoric space.
Metabolite-likeness as the criterion for lead discovery
With the growing knowledge of biochemical pathways
and their cognate metabolites, Hattori et al. [22]
analyzed the molecular diversity of KEGG (Kyoto
Encyclopedia of Genes and Genomes) Ligand database
which includes 9,383 chemical structures. Nobeli et al.
[23] have produced an interesting classification of
Escherichia coli metabolome according to fragment-
based fingerprints and maximum common subgraphs.
Gupta and Aires-de-Sousa [12] compared the structural
coverage of the metabolite molecules from the KEGG
database and purchasable molecules from the ZINC
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compounds. They reported the use of various machine
learning techniques like Kohonen maps, random forest
(RFs) and classification trees to distinguish between
metabolites and non-metabolites. Cherkasov [24] and
coworkers derived 20 binary classifiers and achieved
99% of the accurate separation between drugs, drug-like
compounds (“druglikes”), bacterial and human meta-
bolites and antimicrobial compounds, and proposed
metabolite-likeness as a potential tool for discovering
novel antimicrobials. Recently, Dobson et al. [25]
compared different molecular properties among human
metabolites, drugs and “predrugs” (precursor drug
molecules). They concluded that although metabolites
are a distinct class of compounds, metabolites and drugs
occupy a significant amount of common property space.
They further suggested that metabolite-likeness may be
used as a filter for designing drugs which are functionally
similar to metabolites and thus have better ADMET
properties.
The several excellent studies described above have each
compared different datasets, using a variety of chemoin-
formatics tools and molecular descriptors. Furthermore,
some of the studies used datasets that were clustered [25],
while others have searched or compared complete
(unclustered) datasets [24]. Most importantly, the prop-
erty space of toxic compounds has not been included in
any of these studies, whereas one of the basic tenets of
drug development to reduce or eliminate toxicity [26].
The analysis carried out of the drug failures during past
few decades have shown that over 90% of the failures are
due to high toxicity [27,28]. It is therefore essential that
the property space of toxins is explored along with drugs
and metabolites to develop filters for toxicity.
Our aim is to compare freely available datasets of
metabolites, drugs and toxins, as benchmark datasets,
using a range of available molecular descriptors, to
identify the property space occupied by these three data
types. We also present analysis results from complete
datasets, as well as clustered datasets, to determine
whether clustering molecules would affect the analysis
results. Our results indicate that clustering does not
affect property distributions to a significant level and
that unclustered datasets can be used in drug discovery
pipelines. We also report, for the first time to the best of
our knowledge, that current drug molecules are more
akin to toxins than to metabolites, in physicochemical
property space.
Results
Rule of five (Ro5) analysis
The number of molecules adhering to Ro5 was calcu-
lated and the results are reported in Table 1. It is
surprising to note that although Ro5 was formulated to
pick out drugs or drug-like molecules, it actually does
well in identifying toxin molecules. Over 90% of the
toxin molecules satisfy all Ro5 criteria. On the other
hand, metabolites perform worst among the three
datasets while drugs do fairly well, as expected due to
the predominance of Ro5 over the past decade. It should
also be noted that among the four properties compared,
the numbers of hydrogen bond donor and acceptor seem
to be more robust properties, as over 84% of the
molecules in all the datasets satisfy Ro5 requirements.
Examining the molecular properties of three datasets
The distribution of various descriptors (properties)
among drugs, human metabolites and toxin molecules
a r ea v a i l a b l ef r o mT a b l e2a n dF i g .1 ,2 ,3 ,4 ,b a s e do n
the analyses of clustered datasets (details in the Methods
section). There is very little overlap in the clustered
datasets and so no further reduction in redundant data
has been carried out (details in the Methods section and
Fig. 5).
While there is a multitude of molecular descriptors
available for carrying out comparison studies, given the
l a r g es i z eo ft h ed a t a s e t s ,w en e e das e to fr a p i d l y
computable molecular descriptors, for efficient analysis.
Furthermore, to account for 70% of the drugs, Oprea et
al. [9] used simple descriptors such as the count of rings
and rotatable bonds along with Lipinski descriptors. We
have considered a range of 1D and 3D properties for the
current analysis. The results are presented as Lipinski
(Ro5) properties, 1D properties (non-Ro5 measures) and
3D properties.
Table 1: Distribution of molecules following Lipinski's rule
Datasets Lipinski Properties
Molecular weight < 500 Da H-bond Donor <=5 H-bond Acceptor <=10 Log P < 5
HMDB (Metabolites) 34% 84% 84% 35%
DDB (Drugs) 84% 86% 87% 92%
CPDB (Toxins) 94% 98% 97% 92%
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Molecular weight
Metabolites follow a bimodal distribution in molecular
weight, with the first peak at 100-400 (almost 31% of
the dataset) and the second and larger peak at 700-1000,
containing 48% of the dataset. On the other hand, the
molecular weight of drugs follows a Gaussian distribu-
tion with the majority of drugs (82%) under the range of
500. This is in accordance with the Lipinski restriction of
weight less than or equal to 500. Despite the Ro5
restriction, 18% of the drug molecules possess a
molecular weight in excess of 500. Toxin molecules
more or less follow the same pattern as drugs, with the
gradual decrease in number of compounds as molecular
weight increases from 100 to 500 (Fig. 1a).
From the calculated mean and median values for the
molecular weight, it appears that the metabolite data is
skewed towards high molecular weight compounds
whereas drugs and toxin molecules prefer a lower
molecular weight distribution. The statistics of the
molecular weight property for the three datasets are
available in Table 2.
Lipophilicity (Alog P)
Lipid solubility is a direct measure of transport abilities
of the compound across biological membranes [29].
Drug molecules should have enough solubility to
traverse the membrane but should not be too soluble
so as to get trapped in them. Thus, lipophilicity of a
compound is of special significance in drug discovery
programs. The most commonly used parameter to
evaluate lipid solubility is the n-octanol/water partition
coefficient (Alog P). Positive values of this partition
coefficient correspond to a preference for lipophilic or
hydrophobic environment while negative values indicate
a preference for lipophobic or hydrophilic environment.
It is clear from Table 2 and Fig. 1b, that metabolites in
general are more lipophilic than drugs or toxic com-
pounds. Only 17% of the metabolites have negative Alog
P values confirming that the majority of the metabolites
are lipophilic. On the other hand, 39% of the drugs have
Alog P values in negative territory, indicating that two-
fifths of the drugs are lipophobic. Like metabolites, only
19% of the toxin molecules have negative Alog P values
while the majority of the molecules are in the range 0 to
+5 which is much smaller range as compared to
metabolites (Fig. 1b).
Lipinski hydrogen bond donors
Lipinski hydrogen bond donors (LHBDs) are determined
by counting the numbers of OH and NH bonds in each
molecule [3]. Approximately 21% of the metabolites,
12% of the drugs and 34% of the toxin molecules do not
Table 2: Comparison of molecular properties among the three datasets
Molecular Property Mean (Median) ± std. dev.
Metabolites Drugs Toxins
Lipinski properties
Molecular weight 621 (701) ± 322 355 (309) ± 259 275 (239) ± 167
Alog P 7 (10) ± 7 .08 (1) ± 3.5 2 (2) ± 2
Lipinski HB acceptors 9 (9) ± 6 7 (6) ± 7 5 (4) ± 4
Lipinski HB donor 3 (3) ± 3 3 (3) ± 4 2 (1) ± 2
1D properties
Number of atoms 43 (51) ± 22 24 (21) ± 8 16 (14) ± 11
Number of carbon atoms 34 (41) ± 18 16 (14) ± 12 12 (10) ± 9
Number of hydrogen atoms 60 (72) ± 33 23 (19) ± 18 16 (12) ± 12
Number of nitrogen atoms 1 (1) ± 2 3 (2) ± 3 2 (1) ± 2
Number of oxygen atoms 8 (8) ± 5 5 (4) ± 5 3 (2) ± 3
Number of rings 1 (0) ± 2 3 (2) ± 2 2 (2) ± 2
Number of ring assemblies 1 (0) ± 1 2 (2) ± 1 1 (1) ± 1
Number of rotatable bonds 27 (37) ± 20 6 (4) ± 7 3 (2) ± 4
Number of aromatic bonds 1 (0) ± 4 8 (6) ± 7 6 (6) ± 6
Log D 6 (9) ± 7 0.4 (0.9) ± 4 2 (1.4) ± 2.6
Mol. solubility -10 (-13) ± 8 -3 (-3) ± 3 -3 (-2) ± 3
3D properties
Mol. SA 651 (788) ± 343 364 (316) ± 252 270 (233) ± 159
Mol. volume 450 (548) ± 244 245 (214) ± 170 179 (153) ± 110
Mol. polar SA 143 (126) ± 94 121 (95) ± 117 84 (63) ± 76
Mol. SA volume 866 (1051) ± 420 510 (464) ± 272 401 (366) ± 164
Mol. polar sa SA 216 (195) ± 138 191 (156) ± 173 126 (105) ± 91
Mol. sa SA 1034 (1205) ± 472 578 (523) ± 313 451 (408) ± 187
For each dataset, the mean, median and standard deviation values are provided, with properties ordered as Lipinski properties, 1D properties and 3D
properties. HB: hydrogen bond; Mol.: Molecular; sa: solvent accessible; SA: Surface Area.
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molecules in the drug (~41%) and toxin (~36%) dataset
have one or two LHBDs, respectively, while only 17% of
the metabolite dataset has the same number of LHBDs.
Only 5% of the toxins, 14% of the drugs and 16% of the
metabolites have LHBD greater than five (Fig. 1c).
Lipinski hydrogen bond acceptor
Only a fraction of molecules in all the datasets (0.35% of
metabolites, 0.40% of drugs and 3.6% of toxins) do not
possess Lipinski hydrogen bond acceptors (LHBAs),
computed by summing the numbers of nitrogen and
oxygen atoms in each molecule [3]. Drugs and toxins
follow almost the same distribution with the highest
percentage of molecules in the range 2-7 LHBA atoms
per molecule. On the other hand, metabolites have a
wide spread distribution with an unusually high peak at
9L H B A( F i g .1 d ) .
1D properties
Total number of Atoms
The distribution of the total number of atoms in
metabolites follows a bimodal pattern (Fig. 2a), with
the larger peak at 50-70 atoms, containing 47% percent
molecules and the smaller peak at 10-30 atoms, contain-
ing 28% of molecules. The maximum number of atoms
in a metabolite molecule is 124, while the mean value is
43 atoms per molecule. In contrast to human metabo-
lites, the drug dataset follows a bell-shaped curve,
skewed towards low numbers of atoms per molecule.
Approximately 79% of drugs contain 10-40 atoms per
molecule. The average number of atoms per molecule in
the drug dataset is 24, while in metabolites, the average
is 43. Like drugs, toxin molecules also favor smaller
numbers of atoms per molecule, with a mean of 16 and a
gradual decrease in the number of compounds as the
number of atoms increases per molecule. The majority of
Figure 1
Comparison of Lipinski properties among human metabolites, drugs and toxins. Compared properties include
a. Molecular weight, b. AlogP, c. Number of Lipinski hydrogen bond donors and d. Number of Lipinski hydrogen bond acceptors.
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whileonly9%oftoxinmoleculescontain30ormoreatoms
per molecule. The overall statistics of the three datasets is
given in Table 2 and show that metabolites tend to have
more atoms than drugs and toxin molecules.
Carbon content
Almost half of the molecules in the metabolite dataset
have carbon atoms in the range 35-55 while 32% have
5-25 carbon atoms per molecule (Fig. 2b). The carbon
atom distribution in metabolites has a mean of 33 atoms
and a maximum of 100. On the other hand, drugs have a
mean of 18 carbon atoms per molecule, with a
maximum of 256 and 76% of drugs have carbon
atoms in the range 5-25. Similar to drugs, toxin
molecules also seem to prefer fewer carbons. In the
toxin dataset, 77% of the molecules have 5-25 carbon
atoms, while 16% have five or fewer carbon atoms. Only
7% of the molecules have more than 25 carbon atoms in
toxin dataset. The distribution of carbon atoms in the
toxin dataset has a mean of 12 and a maximum of 62.
From Table 2, we note that metabolites contain more
carbon atoms than drugs, which in turn have greater
carbon content than toxin molecules.
Nitrogen content
Approximately 40% of metabolites do not have any
nitrogen atom (Fig. 2c), while 45% have only one
nitrogen atom and 16% have two or more nitrogen
atoms per molecule. In sharp contrast to metabolites,
only 15% of drug molecules do not posses nitrogen
atoms while 74% of the molecules have nitrogen atoms
i nt h er a n g e1 - 5 .O nt h eo t h e rh a n d ,3 0 %o ft h et o x i n
molecules are devoid of any nitrogen atom while 66% of
Figure 2
1D Atomic property differences between human metabolites, drugs and toxins. Compared properties include a.
Number of atoms, b. Number of carbon atoms c. Number of nitrogen atoms d. Number of oxygen atoms e. Number of
positively charged atoms f. Number of negatively charged atoms
BMC Bioinformatics 2009, 10(Suppl 15):S10 http://www.biomedcentral.com/1471-2105/10/S15/S10
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and only 3% have six or more nitrogen atoms. From
Table 2 and the values presented above, drugs molecules
clearly possess the most number of nitrogen atoms,
followed by toxin molecules and lastly, metabolites.
Oxygen content
For the three datasets, there is a clear reversal of the trend
for the oxygen atom distribution compared to the
nitrogen atom distribution presented in the previous
section. Only 1% of the metabolite molecules do not
have an oxygen atom as compared to 8% of drugs and 15%
of toxin molecules (Fig. 2d). Furthermore, in metabolite
dataset, 73% of the molecules possess oxygen atoms in the
range2-8,comparedto68%ofdrugsand65%ofthetoxins.
Metabolites comprise more oxygen atoms than drugs,
followed by toxic compounds, with mean values of eight,
five and three, respectively (Table 2).
Number of negatively and positively charged atoms
The fraction of molecules with a single negatively
charged atom in the metabolite dataset (16%) is almost
Figure 3
Other 1D properties compared among human metabolites, drugs and toxins. Compared properties include a.
Number of rings, b. Number of ring assemblies c. Number of rotatable bonds, d. Number of aromatic bonds, e. Log D, f.
Molecular solubility.
BMC Bioinformatics 2009, 10(Suppl 15):S10 http://www.biomedcentral.com/1471-2105/10/S15/S10
Page 7 of 18
(page number not for citation purposes)the same as that containing one positively charged atom
(17%). While the metabolite dataset contains molecules
with more than one negatively charged atom, there are
no molecules with more than one positively charged
atom. The percentage of negatively charged atoms is
smaller in the drug dataset as compared to metabolite
dataset (Fig. 2e and Fig. 2f). Only 5% of drug molecules
contain a negatively charged atom, with only 2%
containing two or more negatively charged atoms,
whereas 8% contain one positively charged atom. On
the other hand, in the toxin dataset, 13% of the
molecules contain one negatively charged atom per
molecule and 5% of molecules contain two or more
negatively charged atoms, whereas 14% of the molecules
in the same dataset contain one positively charged atom
per molecule and 4% contain two or higher positively
charged atoms. The trend of charged atoms among the
three datasets is Metabolites > Toxin molecules > Drugs,
Figure 4
Comparison of 3D properties among human metabolites, drugs and toxins. Compared properties include a.
Molecular surface area, b. Molecular volume c. Molecular polar surface area, d. Molecular solvent accessible volume, e.
Molecular polar solvent accessible surface area, f. Molecular solvent accessible surface area.
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over positively charged ones.
Number of rings
The distribution of number of rings is shown in Fig. 3a.
Although more than 55% of the molecules in the
metabolite dataset are acyclic, 19% contain a single
ring and 21% contain 2-5 rings. In sharp contrast to
metabolites, only 9% of the drugs are acyclic, while
almost 60% contains rings, with a three-way distribution
(~20% each) between one, two and three rings per
molecule. The remaining 23% of drug molecules
contains 4-6 rings, the maximum number of rings
being 38. In the toxin dataset, 19% of the molecules
are acyclic, whereas 68% contain 1-3 rings per molecule.
The remaining 10% of toxins contain four or more rings
per molecule. Thus, the pattern of ring distribution
among the three datasets is Drugs > Toxin molecules >
Metabolites.
Number of ring assemblies
After removing the non-ring bonds from a molecule the
remaining backbone is termed as the ring assembly. As
shown in the Fig. 3b, more than half of the molecules
(57%) in the metabolite dataset have no ring assembly,
while 30% of the molecules have one ring assembly and
13% have two or more ring assemblies per molecule. On
the other hand, in the drug dataset, only 10% of the
molecules are free of ring assembly, whereas 36% and
32% have one and two ring assemblies, respectively.
Furthermore, in the same dataset, 23% molecules
contain more than three ring assemblies per molecule.
Similar to drugs, most of the toxins possess ring
assemblies with only 19% are devoid of any ring
assembly, while 45% molecule have a single ring
assembly. The percentage of molecules with two ring
assemblies in the same dataset is 21% whereas 6% of the
molecules have three or more ring assemblies. The
pattern of ring assemblies is similar to that obtained for
ring distribution in three datasets, being Drugs > Toxin
molecules > Metabolites.
Number of rotatable bonds
The number of rotatable bonds is a measure of
molecular flexibility and is important in determining
oral bioavailability of the drugs [30]. Only 4% of the
molecules in the human metabolite dataset have no
rotatable bonds, whereas 32% have 1-10 rotatable bonds
and 47% of the molecules have rotatable bonds in the
range 36-50 (Fig. 3c). The mean value for rotatable bond
distribution in metabolite dataset is 27, with the
maximum number of rotatable bonds in a metabolite
molecule being 83 (Table 2). Among the drug molecules,
7% are devoid of rotatable bonds, while 79% of
molecules have 1-10 rotatable bonds. Another 12% of
the molecules in this dataset have rotatable bonds in the
range of 10-20. The mean value for rotatable bonds per
molecule in drugs is 6, with a maximum of 170. In
contrast to metabolites and drugs, 15% of toxin
molecules do not possess any rotatable bonds, while
79% of the molecules contain rotatable bonds in the
range of 1-10. The mean value for rotatable bonds in
toxin molecules is 3 and the maximum number of
rotatable bonds in a toxin dataset is 31. Thus,
metabolites are more flexible than drugs and toxins.
Number of aromatic bonds
More than 80% of metabolites do not possess any
aromatic bond. The remaining metabolites have several
aromatic bonds, usually as multiples of five or six. As
shown in Fig. 3d, 6% of the molecules have either five or
ten aromatic bonds, while 8% of molecules have either
six or twelve aromatic bonds. The maximum number of
aromatic bonds in metabolites is 36.
In contrast to metabolites, only 29% molecules of drugs
have no any aromatic bonds. Of the remaining, 12% and
36%, respectively, of drug molecules have aromatic
bonds as multiple of five and six. The maximum number
of aromatic bonds in the drug dataset is 62. On the other
hand, toxin molecules are predominantly aromatic
(61%) with 7% and 42% having aromatic bonds as
multiples of five and six, respectively. The maximum
number of aromatic bonds in the toxin dataset is 46. The
order of aromatic bond distribution is Drugs ≈ Toxin
molecules > Human metabolites, with almost half the
aromatic bonds in all the three datasets being multiples
of five or six.
Figure 5
Venn diagram showing the overlap between the
three clustered datasets.
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For solutes that can ionize, the distribution coefficient
(D) is the ratio of the sum of the concentrations of all
forms of the compound (ionized plus un-ionized) in
each of the two solution phases. logD is thus considered
a better measure of lipophilicity that Alog P. However,
for all three datasets, logD follows the same distribution
as Alog P (Fig 3e and Table 2).
Molecular solubility
Human metabolites have large range of molecular
solubility values for example more than 85% of the
molecules in metabolite dataset have molecular solubi-
lity in the range of -20 to 0. Drug molecules have a
smaller range of molecular solubility as compared to
metabolites, with 87% of the molecules in drug dataset
having molecular solubility values spanning -10 to 0.
Similarly, more than 90% of toxin molecules have a
solubility value in the range -10 to 0. Thus, the most
preferred and common range of molecular solubility
among the three datasets is -10 to 0, which comprises
~85% of the drug and toxin datasets but only 38% of the
metabolite dataset (Fig. 3f and Table 2). The molecular
solubility of metabolites is more than that of drugs,
followed by toxin molecules, which suggests that
m e t a b o l i t e st e n dt od i s s o l v em o r ee a s i l yt h a nd r u g s
and toxins in vivo (aqueous media).
Chirality
Chirality seems to be a distinguishing feature among the
three datasets. The majority of the molecules in the
metabolite dataset (74%) are chiral. Chirality falls
sharply in drugs and toxic compounds to 31% and
14%, respectively.
Number of halogen atoms per molecule
As expected, toxin molecules have the highest number of
halogen atoms per molecule compared to metabolites
and drugs. 31% of molecules in toxin dataset possess a
single halogen atom (F, Cl, Br, I) per molecule while in
case of drugs close to 18% contain halogen atoms. In
sharp contrast, to these two datasets, metabolites have
far fewer halogen atoms per molecule. Only 15 out of
4568 molecules, i.e. only 0.3% of the molecules, studied
are reported to have any halogen atom. The trend for
halogens is Toxin molecules > Drugs >> Metabolites. The
statistics provided in Table 3 provides information on
the number of halogen containing molecules in each
dataset.
Number of Sulphur and Phosphorus atoms per molecule
Only 5% of the molecules in metabolite dataset, 20% of
the drugs and almost the same percentage (16%) of
toxin molecules contain one or more sulphur atoms in
their molecule. For sulphur atoms, the trend is Drugs ≈
Toxin molecules > Metabolites. The trend gets reversed in
the case of phosphorus atoms, with 46% of molecules in
metabolites, 13% of drug molecules and only 3% of the
toxic dataset having one or more phosphorus atoms. So
thetrendinphosphorusatomdistributionisMetabolites>>
Drugs > Toxin molecules.
Average bond length per molecule
The metabolite molecules form two groups, with 48%
having a mean value of 0.82 Å bond length, while
another 51% have 0.83 Å. The majority of drug
molecules (65%) also have either 0.82 or 0.83 Å bond
length. In sharp contrast to the other two datasets, the
average bond length for 92% of molecules in toxic
dataset is 1.33 Å, while another 7% of the molecules
have 1.40 Å as the average bond length. As far as average
bond length is concerned, metabolites and drugs have a
much shorter average bond length compared to toxin
molecules, the trend being Toxin molecules > Metabo-
lites ≈ Drugs.
3D Descriptors: molecular volume and surface area
Molecular surface area
Molecular surface area distribution in metabolites is
bimodal (Fig. 4a) with the first smaller peak at 100-400
Å
2, containing 37% of the molecules and the second
larger peak at 700-1100 Å
2, with 53% of the molecules.
On the other hand, 83% of drugs molecules have
molecular surface area between 100-500 Å
2.As i m i l a r
distribution is obtained for toxin molecules with 89% of
the compound in the toxin dataset having a molecular
surface area in the range 100-500 Å
2 and only 4% are in
the range 0-100 Å
2. From these values and the statistics
in Table 2, metabolites have greater molecular surface
area than drugs and toxin molecules.
Table 3: Halogen atom frequency distribution. The number of times different halogens are reported in each of the dataset is listed
below
Database Fluorine Chlorine Bromine Iodine
Metabolites 15 32 0 27
Drugs 496 477 110 63
Toxins 62 473 38 5
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The results of molecular volume distribution in three
datasets are reflected in the related property of molecular
weight distribution. As depicted in Fig. 4b the molecular
volume range in metabolites is much wider and in
accordance with molecular weight data when compared
to the other two datasets. Almost 47% of the molecules
have molecular volume in the range of 500-700 Å
3.T h e
majority of molecular volume distribution of the drug
dataset is narrow compared to that of human metabo-
lites with 81% of the molecules are in the range form
100-400 Å
3, although the tails extend further, with some
molecules found to have volumes above 1700 Å
3.T h e
molecular volume range is even more restricted in toxic
compounds with 90% of the molecules in the range
0-300 Å
3 with ~49% of these having a molecular volume
of 100-200 Å
3. So, the trend for molecular volume
distribution is the same as that observed for molecular
weight distribution among the three datasets: Metabo-
lites > Drugs > Toxin molecules.
Molecular polar surface area
The polar surface area is defined as the surface area
summed over all polar atoms, (usually oxygen and
nitrogen), including the attached hydrogen atoms. It is
often correlated with drug transport capabilities and is
important for penetrating the blood-brain barrier (BBB).
As most of the metabolites do not need to be shuttled
through barriers like BBB, they can afford to have more
polar surface area than drugs and toxins. More than 95%
of the metabolites have polar surface area in the range
0-350 Å
2 (Fig. 4c) while 92% of polar surface area of
drugs is contained within 0-250 Å
2. The distribution is
even narrower for the toxin dataset with 90% of the
molecules in the range 0-150 Å
2.
Molecular solvent accessible volume
Molecular solvent accessible volume distribution is
similar to the distribution of the molecular volume. In
the case of metabolites (Fig. 4d), it also follows a
bimodal distribution with a smaller peak of 36%
molecules around 200-600 Å
3 and a larger peak contain-
ing 46% of the molecules around 1000-1300 Å
3.
However, there is no molecule with accessible volume
less than or equal to 100 Å
3. Unlike metabolites, drugs
molecules have only one peak covering almost the entire
dataset. About 91% of the drug molecules have solvent
accessible volume from 200 to 800 Å
3. Like metabolites
there is no molecule with solvent accessible volume less
than or equal to 100 in drug dataset. The distribution of
solvent accessible volume in toxin molecules is even
thinner with 89% of the molecules in the range 200-600
Å
3. Other 7% are present in the range 600-1000 Å
3.
According to the statistics shown in Table 2 and Fig. 4d,
the order of molecular solvent accessible volume is
Metabolites > Drugs > Toxin molecules.
Molecular polar solvent accessible surface area
Drugs and toxin molecules follow a perfect Gaussian
distribution for polar solvent accessible surface area
while metabolites follow a bimodal pattern (Fig. 4e).
The maximum number of molecules in toxic dataset has
molecular polar solvent accessible surface area is in the
range 0-200 Å
2 while for drugs the range is 0-350 Å
2.O n
the other hand maximum numbers of metabolites are
covered in between 100-250 Å
2. The statistics in Table 2
suggests that metabolites tend to have larger molecular
polar solvent accessible surface area compared to drugs
w h i c hi nt u r na r el a r g e rt h a nt o x i n s .
Molecular solvent accessible surface area
Differences among metabolites, drugs and toxin mole-
cules are readily observable for molecular solvent
accessible surface area. Metabolites follow a bimodal
distribution whereas drugs and toxins follow a Gaussian
distribution (Fig. 4f). Toxin molecules peak at 300-500
Å
2 while drugs peak at 400-600 Å
2.M e t a b o l i t e s ,o nt h e
other hand, form a lower peak at 300-400 Å
2 with a
second larger peak at 1200-1500 Å
2.F o r mT a b l e2 ,
metabolites have clearly larger values for molecular
solvent accessible surface area than drugs and toxins.
Functional group analysis
The frequency of functional group occurrence among the
three datasets was carried out in this study with the
Scitegic Pipeline pilot software (details in the Methods
section). The occurrence of specific functional groups of
interest to drug design is giv e ni nT a b l e4a n dA d d i t i o n a l
file 1. Aromatic atoms are a prominent feature among
drugs and toxins while only a sixth of metabolites have
aromatic atoms. The same trend is observed in benzene
ring distribution among the datasets. Further, primary
and quaternary amines occur more frequently in
metabolites than secondary and tertiary amines when
compared to drugs and toxin molecules, respectively.
Additionally, drugs are found to possess a greater
number of amides than metabolites or toxins. Finally,
toxic functional groups (like nitro, azo and cyanide) are
only found in toxins while they are either absent or very
limited in drugs and metabolites.
Clustered vs. unclustered datasets
We have compared all the above property distributions
for clustered and unclustered (raw) datasets (data not
shown). Correlation coefficients were calculated for all
the properties and eight properties which are not
significantly correlated are presented here, viz. Alog P,
molecular weight, the number of oxygen atoms, the
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area, molecular solubility, the number of rings and the
number of aromatic bonds (Figs. 6, 7, 8, 9). Alog P and
molecular weight values (Fig. 6) do not deviate
significantly with clustering. Nitrogen atom distribu-
tion (Fig. 7) for clustered and unclustered molecules
also remains fairly similar for all the datasets. The
analysis also shows that the number of aromatic bonds
(Fig. 8) and the molecular solubility distribution
(Fig. 9) are also fairly conserved between clustered
and unclustered datasets. We note that, by and large,
the two distributions are very similar except in
following cases:
Number of oxygen atoms
There is an exception at five oxygen atoms per molecule
in the unclustered metabolite dataset (Fig. 7b).
Number of rings
The number of molecules with zero rings drops for drugs
(~8% decrease) and toxins (~9% decrease) whereas
metabolites follow a similar distribution in clustered and
unclustered dataset comparison (Fig. 8a).
Molecular polar surface area
Clustered metabolites show a 10% decrease in molecules
with polar surface area in the range 50-100 Å
2 while
clustered toxins show a 15% increase in the number of
molecules with polar surface area between 0 to 50 Å
2.
Drugs, on the other hand, follow a similar distribution
for clustered and unclustered datasets (Fig. 9a).
Conclusion
We have carried out a comprehensive analysis of three
publicly available datasets, comprising drug, metabolite
and toxin molecules. We have also, for the first time, to
the best of our knowledge, compared the distributions of
various properties for complete datasets (unclustered
data) as well as reduced or clustered datasets. We note
that, in the main, the distributions for the two data
groups, clustered and unclustered, are very similar,
supporting the use of clustered datasets, except in the
case of the number of oxygen atoms, the molecular polar
surface area and the number of rings. Based on this
result, these properties should be treated with caution
for lead discovery in drug discovery pipelines with
unclustered datasets.
From the analyses of clustered datasets, we find that two-
thirds of the human metabolites lie outside the Lipinski
universe. On the other hand, over 90% of the toxin
molecules abide by Lipinski’s rule, implying that since
Ro5 does not explicitly take toxicity into account,
present-day drugs are consequently similar to toxins
than to metabolites.
Results from the analysis of 1D and 3D molecular
properties consolidate our finding of drugs and toxins
sharing a larger property space, than drugs and metabo-
lites. 1D properties such as the total number of atoms
advocate that metabolites are bulky, with more carbon
and hydrogen atoms than drug and toxins. This is
consistent with the idea that metabolites are produced at
the required subcellular location and thus do not need
to be transferred from one location to another. In order
to design metabolite-like drugs, it would be beneficial to
attempt alternative ways for drug delivery, since tradi-
tionally, drugs are required to pass through the blood-
brain-barrier, which limits the size of drug molecules.
Considering the numbers of nitrogen and oxygen atoms,
metabolites prefer oxygen over nitrogen containing
groups. Above 50% of the metabolites are acyclic while
only 9% of the drugs and 19% of the toxin molecules are
acyclic. The number of rotatable bonds measuring
molecular flexibility and consequently, oral bioavail-
ability, suggests that metabolites are far more flexible
than drugs and toxin molecules. Over 70% of the drugs
and 62% of toxin molecules are aromatic while only
20% of the metabolites are aromatic. This result is in
accordance with the fact that drugs are derived from
various sources including NPs which are mostly aromatic
in nature. In all the datasets examined, the majority of
molecules have negative solubility values, suggesting
that a large proportion of these compounds are soluble
in aqueous solutions. Chirality falls sharply from
metabolites to drugs and toxin molecules while as
expected, the number of halogen atoms are found to
Table 4: Occurrence of functional groups in the three datasets
Functional Group Metabolite
dataset
Drugs
dataset
Toxin dataset
Alkyl halide <0.5% <0.5% 3.2%
Aromatic atom 17.4% 70.6% 62.3%
Benzene 10.3% 56.0% 53%
Steroid backbone 2.9% 0.6% <0.5%
HBA Ester 56.3% 13.8% 15.4%
Pyridine 1.2% 6.4% 5.3%
Pyrimidine 3.2% 7.5% 1.9%
Enamine 3.2% 10.31% 3.41%
Primary amine 28% 14.4% 12.0%
Secondary amine 11.4% 64.0% 41.2%
Tertiary amine 44.6% 80.0% 60.0%
Quaternary Amine 15.3% 2.1% 0.5%
Primary amide 1.5% 4.5% 3.9%
Secondary amide 11.4% 31.0% 14.5%
Tertiary amide 2.8% 16.8% 9.2%
Imines 4.1% 14.0% 6.4%
Azo 0% <0.5% 3.4%
Carbamic acid <0.5% 3.1% 1.9%
Urea 2.5% 8.0% 6.5%
Those functional groups which can discriminate between the three
datasets are presented here. The complete list is in Additional File 1.
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average bond length of 90% metabolites and more than
65% of drugs is much smaller than majority of toxins,
suggesting multiple bonds in the former datasets. The
analysis results from 3D descriptors such as molecular
volume and molecular surface area are reflected in the
related property of molecular weight and confirm that
present day drugs are more like toxins than metabolites.
The analysis also shows that although drugs share a
relatively larger property space with toxins than with
metabolites, drugs and toxins are two different classes of
compounds as reflected in specific physicochemical
characteristics. Drugs tend to have higher values for
properties such as molecular weight, the number of
oxygen atoms, the number of rotatable bonds and
molecular polar surface area whereas toxin molecules
have considerably higher Alog P and Log D values.
Additionally, empirical rules like the “rule of five” can be
refined to increase the coverage of drugs or drug-like
molecules that are clearly not close to toxic compounds,
because toxicity reduction is one of the key aspects of
drug discovery programs. Our results have implications
Figure 6
Comparison of example Lipinski properties for clustered and unclustered (raw) data. Properties compared are
a. Alog P, b. Molecular weight,, for human metabolites (M), drugs (D) and toxin molecules (T).
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pipelines, to uncover novel target molecules.
Methods
Preparation of the dataset
Three publicly available databases, relevant to human
diseases and their treatment have been used in this
study. The human metabolome database [31] contains
information on nearly 7000 small molecule metabolites
found in human body. Similarly, DrugBank [32] is a
comprehensive resource on drugs and drug targets, with
detailed chemical, pharmaceutical and medical informa-
tion on nearly 3000 drug targets and 4800 drugs
including >1,350 FDA-approved small drugs and experi-
mental drugs derived from the PDB-Ligand database
[33], containing compounds bound to biomolecules.
Distributed Structure-Searchable Toxicity (DSSTox)
Carcinogenic Potency Database [34] is hosted by the
US Environmental Protection Agency’s National Center
for Computational Toxicology aiming to provide a
public data repository on toxicity data. DSSTox contains
experimental results and carcinogenicity information for
1547 substances tested against different species.
Preliminary datasets containing 6668 human metabolites
from the human metabolome database (as on 23-Dec-
2008), 4883 drugs from DrugBank (as on 6-Jan-2009) and
1547 toxin molecules from DSSTox (as on 16-Jan-2009)
were extracted.
From these preliminary datasets duplicates and inorganic
molecules (individual atoms, metal salts, inorganic oxides,
hydroxides, cations and anions) were removed. Any
“missing” compounds (either with no or incomplete
structure) were also removed. The “cleaned” collections of
Figure 7
Comparison of example 1D atomic properties for clustered and unclustered (raw) data. Properties compared a.
Number of nitrogen atoms, b. Number of oxygen atoms, for human metabolites (M), drugs (D) and toxin molecules (T).
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containing 6582 metabolites, 4829 drug molecules and
1448 toxin molecules. Finally, clusters were generated from
eachdataset, usingthe Cluster“Clara” algorithm embedded
in the Scitegic Pipeline Pilot software [35], which is an
approximate version of “partitioning around medoids”
(pam) method comprising 70% of the entire raw data,
similartothatreportedinDobsonetal.[25].Clusteringwas
performed to address the issue of possible overrepresenta-
tion of the chemical space, which might bias the analysis
results towards these redundant molecules. Representative
setsofmoleculeswereproducedbyemployingtheextended
connectivity fingerprint (ECFP) [36,37] as a molecular
descriptor and Euclidean distance was the distance metric
selected. ECFP generates an array of structural features by
encoding each atom and its molecular environment within
a sphere of specified diameter. Cluster centres were selected
as therepresentatives, for clusterscontaining morethan one
molecule while singletons were directly used as cluster
centres in non-cluster situations. The contents of unclus-
tered and clustered datasets, prepared for analyses are
presented in Table 5.
The overlap among the three clustered datasets (CM, CD
and CT) was calculated and it was found that more
compounds are common in between drugs and toxin
molecules than any other combination. The results are
displayed in Figure 5. As the binary overlap is very small
(<5%) and the ternary overlap is negligible, the datasets
were retained as such, without further size reduction.
Calculations of the physicochemical properties
The calculation of all the molecular properties was
carried out through the Scitegic pipeline pilot [35] and
in-house Perl scripts.
Two types of hydrogen bond acceptors and donors were
taken into account. Firstly, the Lipinski type donors (sum
Figure 8
Comparison of example 1D aromatic properties for clustered and unclustered (raw) data. Properties compared
are a. Number of rings, b. Number of aromatic bonds, for human metabolites (M), drugs (D) and toxin molecules (T).
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were calculated as defined by Lipinski et al. [3] and then,
all available hydrogen bond donors and acceptors were
summed up.
The octanol-water partition coefficient was either
retained if provided with the data, or was calculated
from Scitegic software. The hydrophobicity measure,
Alog P, was calculated using the Ghose-Crippen method
[38] which takes into account the group contribution to
Log P. Another partition coefficient, Log D (the
distribution coefficient), which take into account union-
ized and ionized species, was also calculated. Log D is
equal to Log P for unionizable compounds but with
ionized species, Log D is considered better than Log P, as
it takes ionized species into account, along with union-
ized forms. A positive value of Log P or Log D suggests a
Figure 9
Comparison of example molecular properties important in drug design, for clustered and unclustered (raw)
data. Properties compared are a. Molecular polar surface area, b. Molecular solubility, for human metabolites (M), drugs (D)
and toxin molecules (T).
Table 5: Clustered and Unclustered datasets
Dataset Metabolites Drugs Toxin molecules
Unclustered M: 6582 D: 4829 T: 1448
Clustered CM: 4568 CD: 3248 CT: 995
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(page number not for citation purposes)preference to lipophilic surroundings, whereas a negative
value indicates preference to lipophobic (or hydrophilic)
environment.
Log D C C io c t ia q = ∑ ∑[] / [] (1)
Other simple count-based molecular descriptors enu-
merating aromatic bonds, atoms, carbon atoms, nitrogen
atoms, oxygen atoms, hydrogen atoms and rings were
also calculated. Beside these, one-dimensional (1D)
descriptors calculated include molecular weight and
molecular solubility. Three-dimensional (3D) descrip-
tors like molecular volume, molecular surface area,
molecular polar surface area and molecular solvent
accessible surface area were also computed. The mole-
cular polar surface area is defined as the sum of all the
polar atoms (usually oxygen and nitrogen atoms, and
the attached hydrogen atoms). This descriptor is often
correlated with drug transport capabilities and is
important in penetrating the blood-brain barrier.
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